New anti-cancer information: The efficacy of adagrasib

Adagrasib, aKRASG12C inhibitor, has shown clinical activity in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) and was well tolerated in this rare Cohort of pre-treated patients with KRASG12C-mutated solid tumors. KRASG12C mutations occur rarely in other solid tumor types.

Adagrasibis an oral small molecule inhibitor of the KRAS gene product, a mutated oncogene commonly found in several forms of cancer, most commonly in non-small cell lung cancer. The KRAS (Christian murine sarcoma viral oncogene homolog) G12C mutation produces a constitutively active protein receptor (a member of the RAS GTPase family) that stimulates excessive cell growth. Adagrasibbinds to the abnormal receptor and locks it in an inactive conformation, thereby inhibiting cell growth and proliferation in tumor cell lines and KRAS G12C mutant experimental tumor models. In a large open-label trial, adagrasib was found to induce objective responses in 43% of patients with refractory non-small cell lung cancer harboring the KRAS G12C mutation. Adagrasib is still being evaluated in other forms of KRAS G12C mutant cancer.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.